NCT02384824

Brief Summary

The purpose of this study is to characterize the plaque morphology in patients with acute STEMI by OCT after aspiration thrombectomy.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2015

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 15, 2015

Completed
2 months until next milestone

First Posted

Study publicly available on registry

March 10, 2015

Completed
22 days until next milestone

Study Start

First participant enrolled

April 1, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2017

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2017

Completed
Last Updated

March 10, 2015

Status Verified

March 1, 2015

Enrollment Period

2 years

First QC Date

January 15, 2015

Last Update Submit

March 9, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • plaque morphology by OCT

    at the 7th day post PCI/aspiration thrombectomy

Secondary Outcomes (2)

  • Re-hospitalization due to cardiac symptoms

    30 days & 12 months

  • Myocardial infarction related to the target vessel

    30 days & 12 months

Interventions

angiography, manual aspiration thrombectomy and antiplatelet therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with acute STEMI

You may qualify if:

  • Age \> 18 years
  • Onset of STEMI \> 30 minutes, but \< 12 hours
  • ST segment elevation in at least 2 contiguous leads of≥ 1mm or newly developed LBBB on ECG
  • Willing and able to provide informed consent
  • Having at least one infarct-related coronary artery, of which
  • The Culprit lesion is suitable for stenting;
  • The reference diameter of culprit vessel is ≥ 2.5 mm but ≤ 4 mm;
  • The TIMI flow is ≤ 1 in culprit lesion segment prior to guide wire crossing
  • No excessive tortuosity and calcification in the culprit lesion segment that allowing stent implantation

You may not qualify if:

  • Contraindicating to any concomitant study medications
  • Having cardiogenic shock with hemodynamic instability
  • A history of bleeding diathesis or known coagulopathy
  • A history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months; or a history of intracranial tumor, aneurysm or arteriovenous malformations; or a history of active peptic ulcer or active gastrointestinal (GI) bleeding within the past 2 months; or planned major procedure within 6 weeks; or known platelet count \< 100,000 /mm3 or Hb \< 10 g/dL
  • Planned surgery which may cause discontinuation of ADP-receptor antagonist
  • Other serious illness (e.g., cancer) that may reduce life expectancy to less than 1 year
  • Repeated MI within 7 days of hospitalization for acute MI
  • Bifurcated lesion unable to identify the culprit lesion
  • The culprit lesion is located in the left main artery
  • Diffusive lesions without distinguishable culprit lesion
  • Previous stent implantation in the culprit lesion segment or STEMI caused by stent thrombosis
  • Likely CABG procedure within 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Coronary Artery DiseaseMyocardial Infarction

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
President of Second Affiliated Hospital, School of Medicine, Zhejiang University & Chief of Cardiology

Study Record Dates

First Submitted

January 15, 2015

First Posted

March 10, 2015

Study Start

April 1, 2015

Primary Completion

April 1, 2017

Study Completion

October 1, 2017

Last Updated

March 10, 2015

Record last verified: 2015-03